TY  - SER
AU  - Aschenbrenner, Diane S.
TI  - Asthma medication receives new warning
SN  - 0002-936X
PY  - 2015///
KW  - Labeling
KW  - Cardiovascular diseases
KW  - Antiallergic agents
KW  - Cancer
KW  - Asthma
KW  - Drugs
KW  - Descriptive labeling
N1  - Nursing
N2  -   The Food and Drug Administration has revised the warnings in the labeling of omalizumab (Xolair), a drug used in the treatment of allergic asthma. Omalizumab's labeling now warns that the drug may carry a slightly elevated risk of cardiovascular complications. Omalizumab is administered every two to four weeks as a subcutaneous injection to patients with moderate-to-severe persistent, allergic asthma and an elevated IgE level and whose allergic asthma symptoms aren't well controlled with corticosteroids
ER  -